医学
PCSK9
重症监护医学
低密度脂蛋白胆固醇
疾病
内科学
生物信息学
胆固醇
低密度脂蛋白受体
脂蛋白
生物
作者
Mahmoud Al Rifai,Christie M. Ballantyne
标识
DOI：10.1038/s41569-021-00634-0
摘要
Human genetic studies combined with biotechnological advances have guided and accelerated the development of PCSK9-targeting therapies. In this Clinical Outlook, we highlight present and future approaches for PCSK9 inhibition to reduce LDL-cholesterol levels and the risk of atherosclerotic cardiovascular disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI
忐忑的黑猫
科研小民工
森鹿
bc
余味
cdercder
平常的毛豆
归尘
Luka
善良的剑通
斯寜
827584450
Xiaoxiao
iNk
蒋时晏
illusion2019
冰魂
小白
Oracle
YifanWang
皖公网安备34019202002308
